title: Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
abstract: The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are associated with substantial vascular and transformative complications. Standard therapy for high-risk disease, particularly in patients that have failed initial therapy, remains controversial. Non-pegylated interferon has previously been shown to be effective in controlling erythrocytosis, thrombocytosis and thrombotic complications, but was found to have poor tolerability and excessive adverse effects. Recently, pegylated interferon alpha-2a was introduced and found to be better tolerated and less toxic than standard interferon. In addition, in recent phase II trials, pegylated interferon alpha-2a therapy was found to induce both hematologic and molecular remissions. We retrospectively analyzed 118 myeloproliferative patients who underwent pegylated interferon alpha-2a treatment. Responses were evaluated by ELN, IWG-MET and EUMNET standardized criteria sets and adverse effects were analyzed.
authors.affiliation: University of Southern California, USA.
authors.forename: Krisstina
authors.initials: K
authors.lastname: Gowin
authors.forename: Prakash
authors.initials: P
authors.lastname: Thapaliya
authors.forename: Jan
authors.initials: J
authors.lastname: Samuelson
authors.forename: Claire
authors.initials: C
authors.lastname: Harrison
authors.forename: Deepti
authors.initials: D
authors.lastname: Radia
authors.forename: Bjorn
authors.initials: B
authors.lastname: Andreasson
authors.forename: John
authors.initials: J
authors.lastname: Mascarenhas
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
authors.forename: Catherine J
authors.initials: CJ
authors.lastname: Rea
authors.forename: John
authors.initials: J
authors.lastname: Camoriano
authors.forename: Amy
authors.initials: A
authors.lastname: Gentry
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Kiladjian
authors.forename: Casey
authors.initials: C
authors.lastname: O'Connell
authors.forename: Ruben
authors.initials: R
authors.lastname: Mesa
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a